Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07511036 · ClinicalTrials.gov registry record · Phase 2
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07511036: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07511036 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07511036, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.
Interventions
- DRUG Cemiplimab
- DRUG Fianlimab
- DRUG Lpilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07511036
The ClinicalTrials.gov registry entry for NCT07511036 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cemiplimab is the first listed.
NCT07511036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07511036 about?
NCT07511036 is a clinical study titled "PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma". This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.
What is the current status of trial NCT07511036?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-09-01. Estimated completion is 2030-05-24.
What interventions are being tested in trial NCT07511036?
The interventions under investigation include: Cemiplimab (DRUG), Fianlimab (DRUG), Lpilimumab (DRUG).
Who is sponsoring clinical trial NCT07511036?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.